Summary
Global Markets Direct’s, ‘Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Kyowa Hakko Kirin Co., Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Kyowa Hakko Kirin Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Kyowa Hakko Kirin Co., Ltd.
- The report provides overview of Kyowa Hakko Kirin Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kyowa Hakko Kirin Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kyowa Hakko Kirin Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Kyowa Hakko Kirin Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kyowa Hakko Kirin Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kyowa Hakko Kirin Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Kyowa Hakko Kirin Co., Ltd. Snapshot 8
Kyowa Hakko Kirin Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Kyowa Hakko Kirin Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Kyowa Hakko Kirin Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products Glance 19
Kyowa Hakko Kirin Co., Ltd. - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Kyowa Hakko Kirin Co., Ltd. - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Kyowa Hakko Kirin Co., Ltd. - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
Kyowa Hakko Kirin Co., Ltd. - Drug Profiles 25
brodalumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
darbepoetin alfa 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
granisetron ER 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
romiplostim 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tivozanib hydrochloride 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
benralizumab 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
burosumab 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
istradefylline 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mogamulizumab 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MT-4580 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tivantinib 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bardoxolone methyl 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bleselumab 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KHK-4083 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BIW-8962 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
antithrombin III (human) 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
entinostat 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
KHK-2823 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KHK-2898 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
KHK-6640 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CHKM-4927 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
K-685 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
K-756 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
KHK-KRAS 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
KHK-XXX 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
KM-2812 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Pr-1E11 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Z-3G1 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
K-777 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Kyowa Hakko Kirin Co., Ltd. - Pipeline Analysis 76
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Target 76
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Route of Administration 78
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Molecule Type 79
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action 80
Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates 82
Kyowa Hakko Kirin Co., Ltd. - Dormant Projects 115
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products 116
Discontinued Pipeline Product Profiles 116
AGS-004 116
darbepoetin alfa 116
KHK-2866 117
KHK-6188 117
KRN-330 117
KRX-0601 117
KW-2449 117
KW-2450 117
KW-2478 118
KW-7158 118
litronesib 118
mogamulizumab 118
pibrozelesin hydrobromide 118
rocapuldencel-t 118
SAR-252067 119
tivantinib 119
tivozanib hydrochloride 119
Kyowa Hakko Kirin Co., Ltd. - Company Statement 120
Kyowa Hakko Kirin Co., Ltd. - Locations And Subsidiaries 121
Head Office 121
Other Locations & Subsidiaries 121
Appendix 124
Methodology 124
Coverage 124
Secondary Research 124
Primary Research 124
Expert Panel Validation 124
Contact Us 124
Disclaimer 125
List of Tables
Kyowa Hakko Kirin Co., Ltd., Key Information 8
Kyowa Hakko Kirin Co., Ltd., Key Facts 8
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Indication, 2016 10
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Stage of Development, 2016 13
Kyowa Hakko Kirin Co., Ltd. - Monotherapy Products in Pipeline, 2016 14
Kyowa Hakko Kirin Co., Ltd. - Partnered Products in Pipeline, 2016 15
Kyowa Hakko Kirin Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 16
Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products in Pipeline, 2016 17
Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 18
Kyowa Hakko Kirin Co., Ltd. - Pre-Registration, 2016 19
Kyowa Hakko Kirin Co., Ltd. - Phase III, 2016 20
Kyowa Hakko Kirin Co., Ltd. - Phase II, 2016 21
Kyowa Hakko Kirin Co., Ltd. - Phase I, 2016 22
Kyowa Hakko Kirin Co., Ltd. - Preclinical, 2016 23
Kyowa Hakko Kirin Co., Ltd. - Discovery, 2016 24
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Target, 2016 76
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Route of Administration, 2016 78
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Molecule Type, 2016 79
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 80
Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates, 2016 82
Kyowa Hakko Kirin Co., Ltd. - Dormant Developmental Projects,2016 115
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products, 2016 116
Kyowa Hakko Kirin Co., Ltd., Other Locations 121
Kyowa Hakko Kirin Co., Ltd., Subsidiaries 122
List of Figures
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Top 10 Indication, 2016 10
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Stage of Development, 2016 13
Kyowa Hakko Kirin Co., Ltd. - Monotherapy Products in Pipeline, 2016 14
Kyowa Hakko Kirin Co., Ltd. - Partnered Products in Pipeline, 2016 15
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Top 10 Target, 2016 76
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Route of Administration, 2016 78
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Molecule Type, 2016 79
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 80
